Want to join the conversation?
Based on the results from Phase 3 HELIOS (CLL3001) trial, Janssen Biotech, a part of $JNJ, has submitted supplemental New Drug Application (sNDA) to U.S. FDA for IMBRUVICA (ibrutinib) plus bendamustine and rituximab for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.